Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Drug Developers Looking to Learn as Much as Possible in Phase I Trials, According to Tufts Center for the Study of Drug Development

By Pharmaceutical Processing | January 27, 2009

Under pressure to develop new medicines more quickly and at lower cost, drug sponsors are looking to answer as many questions as possible in Phase I, including those relating to efficacy as well as safety, according to the Tufts Center for the Study of Drug Development. “The desire to learn more from Phase I studies has led to greater protocol complexity and larger trials, which, with growing regulatory oversight, has helped drive up costs and lengthen timelines, which is just the opposite of what the industry needs to achieve,” said Tufts CSDD Director Kenneth I Kaitin. In addition, developers are increasing their reliance on patient volunteers — now accounting for 38% of all human subjects in Phase I studies — who typically cost more to recruit and retain than healthy volunteers. To help temper, if not reverse, the ever-growing cost of Phase I trials, the research-based drug industry as a whole will likely increase its use of outsourced services and make greater use of biomarkers and diagnostic tests, according Kaitin. Kaitin made his remarks at a meeting of drug industry leaders recently convened by Tufts CSDD to discuss challenges and opportunities in the Phase I landscape. Participants at the meeting, part of Tufts CSDD’s Executive Forum Roundtable Series, noted that: Integrated studies — those with multiple objectives — are likely to grow in popularity, partially in response to financial constraints, especially in smaller organizations. Pressure on drug developers to maximize the amount of information they obtain in Phase I studies will increase pressure on CROs to achieve proof of concept as soon as possible. Public concern over clinical trial safety is likely to keep pressure on sponsors to disclose information about ongoing studies.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards